Personalis (NASDAQ:PSNL) Downgraded to Sell Rating by Wall Street Zen

Wall Street Zen downgraded shares of Personalis (NASDAQ:PSNL) from a hold rating to a sell rating in a research report sent to investors on Saturday morning.

A number of other research firms have also recently commented on PSNL. BTIG Research boosted their target price on shares of Personalis from $12.00 to $13.00 and gave the stock a “buy” rating in a research report on Wednesday, February 11th. Guggenheim upped their price objective on shares of Personalis from $12.00 to $13.00 and gave the company a “buy” rating in a research report on Monday, January 26th. Morgan Stanley lowered their target price on Personalis from $11.00 to $10.00 and set an “equal weight” rating for the company in a research note on Thursday, March 5th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Personalis in a research note on Tuesday, April 21st. Finally, Needham & Company LLC increased their price target on Personalis from $10.00 to $12.00 and gave the company a “buy” rating in a report on Friday, February 27th. Five investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Personalis currently has an average rating of “Moderate Buy” and a consensus price target of $11.50.

Personalis Stock Performance

Personalis stock opened at $5.98 on Friday. The firm has a market capitalization of $625.99 million, a PE ratio of -5.86 and a beta of 1.96. Personalis has a one year low of $3.84 and a one year high of $11.50. The stock’s 50 day moving average price is $6.93 and its 200 day moving average price is $8.23.

Personalis (NASDAQ:PSNL) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($0.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by ($0.06). Personalis had a negative net margin of 148.11% and a negative return on equity of 45.98%. The firm had revenue of $15.47 million during the quarter, compared to analyst estimates of $14.49 million. On average, analysts forecast that Personalis will post -1.01 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Personalis

Large investors have recently added to or reduced their stakes in the company. Aberdeen Group plc raised its holdings in shares of Personalis by 36.1% during the fourth quarter. Aberdeen Group plc now owns 3,249,895 shares of the company’s stock worth $25,869,000 after purchasing an additional 861,948 shares during the period. AIGH Capital Management LLC boosted its holdings in shares of Personalis by 4.5% in the 3rd quarter. AIGH Capital Management LLC now owns 3,892,101 shares of the company’s stock valued at $25,376,000 after buying an additional 168,143 shares during the period. Oracle Investment Management Inc. acquired a new position in shares of Personalis in the 3rd quarter valued at about $1,496,000. ARK Investment Management LLC grew its position in shares of Personalis by 11.3% during the 3rd quarter. ARK Investment Management LLC now owns 7,910,191 shares of the company’s stock valued at $51,574,000 after buying an additional 802,268 shares during the last quarter. Finally, D.A. Davidson & CO. bought a new stake in shares of Personalis during the 4th quarter valued at about $1,158,000. 61.91% of the stock is currently owned by institutional investors.

Personalis Company Profile

Personalis, Inc (NASDAQ: PSNL) is a clinical?stage genomics company that develops and markets advanced next?generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T?cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno?oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in?depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.